Aprogen Inc.

Aprogen Kic Inc.

Cephalon Australia (Vic) Pty Ltd

Evogenix, Ltd.

Vincent Batori

George Kopsidas

Sangsoon Yoon

David S Wilson, Jr

Kwon Pyo Hong

Gregory Coia

Merilyn Sleigh

Irene Koukoulas

Briony Cristiano

Anthony Roberts

Jr Wilson David S

Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Anti-CD43 antibody and use thereof for cancer treatment

The present invention relates to novel osteoprotegerin variant proteins (GYPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these GYPs are also provided. Recombinant vectors and host cells expressing these GYPs are also encompassed as are methods of producing recombinant GYPs. The present invention also relates to compositions comprising these GYPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The GYPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.

Osteoprotegerin variant proteins

The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.

Growing community of inventors

Munich, Germany

Vincent Batori